



Auxellence Announces Name Change, Share Consolidation and Up to \$1 Million Private Placement Financing

VANCOUVER, BC, Thursday, September 15th, 2016 – Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF) (“Auxellence” or the “Company”) today announced that it will be effecting the name change to EVITRADE Health Systems Corp. and a consolidation of its common shares on the basis of one new share for fifteen old shares (1:15). The Company’s consolidated common shares under the company’s new name are expected to begin trading on the Canadian Securities Exchange (“CSE”) on September 20th, 2016. The Company’s new CUSIP is 30050R106 and the new ISIN is CA30050R1064. The Exchange “CSE” will issue a bulletin for any additional details.

The purpose of the consolidation is to increase the Company’s common shares price to facilitate the Company’s ability to meet share price requirements of a possible dual-listing or up-listing onto a senior non-Canadian Marketplace or Exchange. In addition to meeting all regulatory requirements, the Company’s shares will be subject to meeting all conditions of any Marketplace or Exchange, where a listing application is submitted.

“We are excited to continue our relationship with the CSE, as our Canadian Exchange, after trading for over 3 years on their platform. The dedication of management and staff has been second to none and we are deeply appreciative of their commitment to us as an issuer in this next phase of our Company development.” said Sydney Au, Chairman and CEO.

As a result of the share consolidation, each fifteen (15) common shares issued and outstanding immediately prior to September 20th, 2016 will automatically be reclassified without any action of the holder into one new common share. The share consolidation will affect all of the Company’s common shares outstanding and all other shares reserved for issuance immediately prior to the market opening on September 20th, 2016. Therefore, the number of issued and outstanding common shares will be reduced from 109,354,284 to 7,290,286 (subject to fractional treatment). All shares reserved for issuance will be treated in the same manner and details will be provided in the Company’s monthly report and posted on the CSE website under the Company’s micro-site. Each shareholder’s percentage ownership in the Company will remain the same and the proportional voting power remains unchanged afterwards, except for minor changes and adjustments resulting from the treatment of fractional shares.

No fractional shares will be issued as a result of the share consolidation. All Fractional interests of 0.5 or greater will be rounded up to the nearest whole number of shares and fractional interests of less than 0.5 will be rounded down to the nearest whole number of shares. Registered shareholders of the Company will need to obtain a letter of transmittal from the Company’s transfer agent, Reliable Stock Transfer Services Inc., available on the effective date of the share consolidation. The letter of transmittal will enable registered shareholders holding physical certificates to exchange their old share certificates representing pre-consolidation shares for post consolidation common shares, a copy of which is posted on the CSE website under the Company’s micro-site. Until surrendered, each share certificate representing pre-consolidation common shares will represent the number of whole post consolidation common shares to which the holder is entitled as a result of the consolidation. Shareholders who hold their common



AUXELLENC

Health Corporation

shares in DRS format with the transfer agent, brokerage accounts or in "street name" are not required to take any action to effect the exchange of their common shares.

In addition, a non-brokered private placement financing for a minimum of \$500,000 to a maximum of \$1,000,000 CDN will be available and priced in context of the market on the first day of trading, under the new name and symbol CSE:EVA. Details of which will be announced after the close of trading on Tuesday, September 20th, 2016.

"I would like to thank all our shareholders for their continued support, and would like to stress that all shareholders will still own the same percentage proportion in the Company after the consolidation as they did before. Everyone still has the same percentage voting power, before and after the consolidation; the main difference is that with the higher share price we hope to be able to dual-list or up-list onto a senior non-Canadian Marketplace or Exchange. We remain committed to the Company and focused on the business. We are undertaking this sequence of events to provide the Company better opportunities for funding, visibility, and increasing shareholder value." said Sydney Au, Chairman and CEO.

Contact:

Sydney Au, CEO

Auxellence Health Corporation

Email: ceo@auxellence.com

Phone: (604) 780-3311

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/auxellence-health-corporation>

About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)

Auxellence was founded in 2013 to provide online services for resolving common health problems.

The company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

The current focus is on the normalization of cardiometabolic power in terms of blood pressure, blood glucose, and body weight – and the monitoring of the physiological response to medical solicitations, mainly medication, diet, exercise, and lifestyle changes.

About TULIP™

The TULIP™ system is an online self-service intended for adults interested in normalizing blood pressure, heart rate and rhythm, blood glucose, and body weight. Measurement procedures, conditioning protocols, and session schedules are prescribed automatically from data acquired by the user's TULIP™ device – a blood pressure monitor with interactive protocols that can feed medical records and expert systems useful in testing, tracking and treating common health conditions.

The Tulip™ medical device has received Health Canada and CE Mark certifications.



AUXELLENC

Health Corporation

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and on <http://thecse.com/en/listings/technology/auxellence-health-corporation>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.